Literature DB >> 24903673

Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype.

Miguel Rito1, Fernando Schmitt, António E Pinto, Saudade André.   

Abstract

Fibromatosis-like metaplastic carcinoma (FLMCa) of the breast is a rare low-grade spindle cell carcinoma, of which the biological characteristics have not been well studied. This study aims to assess, in FLMCa, immunohistochemical expression of claudins (CLDN) and features connected with the claudin-low subtype, such as the presence of tumor initiating cells (TIC), epithelial-mesenchymal transition (EMT) phenotype, as well as EGFR activating mutations. Three cases of FLMCa were retrieved from our hospital archives. Histological and immunohistochemical characteristics were reviewed. Expression of CLDN-1, CLDN-3, CLDN-4 and CLDN-7, CD44 and CD24 (TIC phenotype), and vimentin and E-cadherin (EMT features) were studied. EGFR mutations on exons 18, 19, 20, and 21 were investigated by real-time PCR. In all cases, the low-grade spindle cell component was predominant, with two cases presenting <5 % of epithelioid and squamous areas. The tumors expressed basal cytokeratins and vimentin and were hormone receptor and ERBB2 negative. CLDN membrane expression was negative in the spindle cell component. The epithelioid areas were CLDN-1 positive. Nuclear/cytoplasmatic expression of CLDN-4 was observed in all components, except in one case in which it was strongly expressed in the non-spindle areas. All three cases were CD44+/CD24-. E-cadherin was focally expressed in epithelioid cells, only in the squamous areas. Activating EGFR mutations were not found. One patient developed local recurrences, metastases and died. FLMCa have the immunohistochemical profile of claudin-low breast tumors, with low expression of adhesion molecules, presence of TIC and EMT phenotype. No EGFR activating mutations were found.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903673     DOI: 10.1007/s00428-014-1603-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

1.  Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice.

Authors:  Angela N Bartley; Dennis W Ross
Journal:  Arch Pathol Lab Med       Date:  2002-04       Impact factor: 5.534

2.  Low-grade (fibromatosis-like) spindle cell carcinoma of the breast.

Authors:  N Sneige; H Yaziji; S R Mandavilli; E R Perez; N G Ordonez; A M Gown; A Ayala
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

3.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

Authors:  Rohit Bhargava; William L Gerald; Allan R Li; Qiulu Pan; Priti Lal; Marc Ladanyi; Beiyun Chen
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

4.  Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.

Authors:  Renê Gerhard; Sara Ricardo; André Albergaria; Madalena Gomes; Alfredo Ribeiro Silva; Ângela Flavia Logullo; Jorge F Cameselle-Teijeiro; Joana Paredes; Fernando Schmitt
Journal:  Breast       Date:  2012-03-30       Impact factor: 4.380

5.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Authors:  Joseph H Taube; Jason I Herschkowitz; Kakajan Komurov; Alicia Y Zhou; Supriya Gupta; Jing Yang; Kimberly Hartwell; Tamer T Onder; Piyush B Gupta; Kurt W Evans; Brett G Hollier; Prahlad T Ram; Eric S Lander; Jeffrey M Rosen; Robert A Weinberg; Sendurai A Mani
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast.

Authors:  Barbara Dunne; Andrew H S Lee; Sarah E Pinder; Jane A Bell; Ian O Ellis
Journal:  Hum Pathol       Date:  2003-10       Impact factor: 3.466

8.  EGFR amplification and lack of activating mutations in metaplastic breast carcinomas.

Authors:  J S Reis-Filho; C Pinheiro; M B K Lambros; F Milanezi; S Carvalho; K Savage; P T Simpson; C Jones; S Swift; A Mackay; R M Reis; J L Hornick; E M Pereira; F Baltazar; C D M Fletcher; A Ashworth; S R Lakhani; F C Schmitt
Journal:  J Pathol       Date:  2006-08       Impact factor: 7.996

9.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

Authors:  Jorge S Reis-Filho; Fernanda Milanezi; Silvia Carvalho; Pete T Simpson; Dawn Steele; Kay Savage; Maryou B K Lambros; Emilio M Pereira; Jahn M Nesland; Sunil R Lakhani; Fernando C Schmitt
Journal:  Breast Cancer Res       Date:  2005-10-25       Impact factor: 6.466

Review 10.  Deconstructing the molecular portraits of breast cancer.

Authors:  Aleix Prat; Charles M Perou
Journal:  Mol Oncol       Date:  2010-11-24       Impact factor: 6.603

View more
  6 in total

Review 1.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Authors:  Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

2.  Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update.

Authors:  Simona Gurzu; Sabin Turdean; Attila Kovecsi; Anca Otilia Contac; Ioan Jung
Journal:  World J Clin Cases       Date:  2015-05-16       Impact factor: 1.337

Review 3.  Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management.

Authors:  Emad A Rakha; Sunil Badve; Vincenzo Eusebi; Jorge S Reis-Filho; Stephen B Fox; David J Dabbs; Thomas Decker; Zsolt Hodi; Shu Ichihara; Andrew H S Lee; José Palacios; Andrea L Richardson; Anne Vincent-Salomon; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Ian O Ellis
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

4.  Clinicopathological features and differential diagnosis of gastrofibromatosis-like undifferentiated carcinoma.

Authors:  Zhishang Zhang; Guang Zhao; Bo Jiang; Baohui Li; Yangkun Wang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

Review 5.  Breast carcinomas of low malignant potential.

Authors:  Stuart J Schnitt; Falko Fend; Thomas Decker
Journal:  Virchows Arch       Date:  2021-07-22       Impact factor: 4.064

6.  Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.

Authors:  Yan-Xi Liu; Ke-Ren Wang; Hua Xing; Xu-Jie Zhai; Li-Ping Wang; Wan Wang
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.